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PRM53
ChoiCe of DistRibutional assuMPtions in Meta-analysis foR the 
evaluation of suRRogate enDPoints
Spata E., Abrams K.R., Thompson J., Bujkiewicz S.
University of Leicester, Leicester, UK
Objectives: In health technology assessment meta-analysis is used to combine 
evidence from a number of studies to inform the decision-making process. When 
evaluating new health technologies at early stages of their development, treat-
ment effects on short-term surrogate endpoints may be used to predict the effect 
on the final outcome that otherwise requires long follow-up time. Meta-analysis 
of multiple outcomes which takes into account the correlations between them is 
particularly suitable for modelling surrogate endpoints. The aim of this study was 
to investigate the choice of distributional assumptions when developing meta-
analytic methods for evaluation of surrogate endpoints. MethOds: Two bivariate 
meta-analytical models are applied to a case study in chronic myeloid leukaemia 
where overall survival (OS) proportion, is the final outcome and complete cytoge-
netic response (CCYR) rate at 12 months is a surrogate endpoint. A normal model on 
log relative risk scale for both outcomes is applied to evaluate CCYR as a surrogate 
endpoint for OS. This model is then extended by relaxing the assumption of nor-
mality by the use of binomial distributions for both outcomes. Results: The effect 
on CCYR was a significant predictor of the effect on OS. Both models gave similar 
results for the effect of CCYR on OS. However, the heterogeneity parameter was 
larger in the binomial model (τ 2= 0.09 with 95% CrI; 0.0 to 0.52) compared to normal 
case (τ 2= 0.07 with 95% CrI; 0.0 to 0.39). cOnclusiOns: The results of both models 
were similar for this case study. However, the choice of distributional assumption 
can lead to different estimates of the effect on the final outcome in other disease 
areas when the normality assumption is not suitable and consequently this can 
impact on HTA decisions.
PRM54
univeRsal CloPiDogRel veRsus CyP2C19-guiDeD antiPlatelet theRaPy 
in Patients With aCute CoRonaRy synDRoMe - a Cost-effeCtiveness 
analysis
Jiang M., You J.
The Chinese University of Hong Kong, Shatin, Hong Kong
Objectives: The gene of CYP2C19 is highly polymorphic and influences the metab-
olism of clopidogrel. Using CYP2C19 genotype data, patients at risk of inadequate 
antiplatelet effect with clopidogrel could be identified and treated with a new 
antiplatelet agent (prasugrel or ticagrelor). This study aimed to evaluate the cost-
effectiveness of genotype-guided therapy versus universal clopidogrel treatment for 
patients with acute coronary syndrome (ACS) undergoing percutaneous coronary 
intervention (PCI). MethOds: A lifelong Markov model, from the perspective of 
healthcare provider, was designed to simulate two treatment strategies: universal 
generic clopidogrel and genotype-guided therapy (generic clopidogrel for patients 
without CYP2C19 loss-of-function (LOF) allele and new oral antiplatelet drug (prasu-
grel or ticagrelor) for patients with at least one LOF allele). Model inputs were derived 
from published meta-analysis and clinical trials. Direct medical costs and quality-
adjusted life-year (QALY) gained were the primary model outcomes. One-way and 
probabilistic sensitivity analyses were performed. Results: Base-case analyses 
illustrated that universal clopidogrel strategy cost $76,335 with 7.919 QALYs, while 
genotype-guided therapy cost $73,131 with 8.068 QALYs. With a threshold of willing-
ness-to-pay of $50,000 per QALY, genotype-guided therapy remained the preferred 
strategy throughout variations of all model inputs in one-way sensitivity analysis 
with no threshold value identified. The most influential factor was the probability 
of ischemic heart disease (IHD) state turned to death, followed by the possibility of 
post myocardial infarction state turned to death, cost of PCI and utility of IHD. In 
probabilistic sensitivity analysis, genotype-guided therapy was dominant with cost-
saving $3472 (95% confidence interval (CI): 3448-3496) and a gain of 0.2425 QALY (95% 
CI: 0.2421-0.2429) compared with universal generic clopidogrel. cOnclusiOns: 
Genotype-guided therapy appears to be the preferred strategy when comparing 
to universal generic clopidogrel treatment for patients with ACS undergoing PCI.
PRM55
Joint estiMation of MaRkov Chain tRansition PRobabilities using 
suRvival MoDels anD ConstRaineD oPtiMization: a Case stuDy on 
Diabetes anD MoRtality anD theiR assoCiation With boDy Mass 
inDex, age, anD genDeR
Wu S.1, Li J.1, Carlsson N.P.2, Leung M.Y.2, Colditz G.A.2, Chang S.2
1Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO, USA, 
2Division of Public Health Sciences, Department of Surgery, Washington University School of 
Medicine, St. Louis, St. Louis, MO, USA
Objectives: We presented an approach to jointly estimate Markov chain transi-
tion probabilities using survival models and constrained optimization to avoid the 
negative probabilities resulting from separate estimations via a case study on dia-
betes and mortality. MethOds: We used data from the National Health Interview 
Survey, 1997-2006, and built a three-state (well, diabetes, and death) Markov model 
with a cycle length of one year. In this model, the transition probability from the 
diabetes state to the well state was assumed to be zero. The other probabilities in 
the transition matrix were jointly estimated based on survival models and con-
strained optimization. First, the probability of developing diabetes and that of death 
were modeled using an exponential survival function, controlling for body mass 
index (BMI), age, and gender. Second, the nonlinear least squares approximation 
method was used to estimate the transition probability from well to well based on 
the data. Last, we simultaneously maximized the combined log-likelihood func-
tions derived from the survival functions under the constraints that the sum of 
the probabilities of all possibilities must add up to one. Results: Using individu-
als aged 50-59 as an example, the transition probability from well to diabetes was 
0.00087 for normal-weight women and 0.00081 for normal-weight men, 0.0015 for 
overweight women and 0.0014 for overweight men, and 0.0034 for obese women 
pleted the questionnaire online. A qualitative analysis of the data, using a combi-
nation of deductive (based on literature) and inductive (based on expert’s opinion) 
approaches were performed using NVIVOv10 Software. Results: A hierarchical 
structure of 100 nodes was designed around 2 main themes: LAIT and chronic graft-
rejection. According to expert interviews, LAIT is a common issue that can have 
significant health consequences. The main drivers of adherence were the number 
of pills and incidence of adverse events. The main consequences identified by the 
experts were antibody mediated graft-rejection and decreased graft survival. CHR 
was identified as the second most common cause of graft rejection between 2-3 
years post-transplant, behind death with a functioning graft. LAIT could cause up 
to 50% of CHR. There is no consensus on treating CHR, but therapies include intrave-
nous immunoglobulins, rituximab and plasmapheresis. Other health resources used 
include: at least one diagnostic renal biopsy, 2-fold increase in follow-up clinical 
visits, a higher risk of hospitalization due to complications (infections, heart-failure 
and anaemia) and preparation for return to dialysis. Most CHR episodes resulted in 
graft loss and return to dialysis with high associated costs. cOnclusiOns: Poor 
adherence is considered a preventable but frequent cause of CHR and graft loss. 
Treatment simplification and education could improve adherence and burden of 
disease for KT patients.
ReseaRCh on MethoDs – Modeling Methods
PRM51
RePliCation of a PublisheD MaRkov ChRoniC MigRaine Cost-
effeCtiveness analysis MoDel foR PuRPoses of eaRly Phase 
aDaPtation anD exPansion
Smolen L.J., Klein T.M., Kelton K.
Medical Decision Modeling Inc., Indianapolis, IN, USA
Objectives: Published cost-effectiveness analysis (CEA) models, especially those 
which have been submitted to health technology assessment (HTA) authorities, 
are valuable in early phase CEA of interventions in the same or similar disease 
areas. However, even well-documented Markov models can be difficult to repli-
cate. Additionally, differences in disease states, treatment effects, and patient 
populations can render a successfully-replicated Markov model non-informative 
for early phase investigations. As a basis for future adaptation and expansion, 
a published chronic migraine CEA Markov model was replicated in TreeAge Pro 
2014 as both a Markov model and as an individual-based state-transition (Monte 
Carlo microsimulation [MCm]) model. MethOds: The published and replicated 
Markov model results were compared for both base case and sensitivity analyses. 
Patient subgroup Markov transition probability (MTP) matrices were implemented 
in the MCm, with assumptions regarding unpublished information on post-initial 
cycle state transitions. These assumptions involved subgroup treatment effects, 
patient decision discontinuation, and treatment stopping rules. The overall patient 
population (OPP) MTP matrices generated by the MCm were loaded into the Markov 
model to assess the validity of the assumptions. Results: Incremental costs 
and quality-adjusted life-years (QALYs) between intervention with onabotu-
linumtoxinA and placebo were produced. Differences between published and 
replicated Markov model incremental cost and QALY results were small for the 
base case (0.0%, -1.1%) and selected sensitivity analyses (maximum differences 
[1.9%, -1.9%]). Base case differences between published and the replicated Markov 
model (using MCm-derived OPP MTP matrices) incremental cost and QALY results 
were larger but acceptable (5.2%, 11.7%). This reflects the assumptions involved 
with the approximation of the patient subgroup MTP matrices. cOnclusiOns: 
The study demonstrates how a published model can be replicated and adapted 
for early phase CEA investigations, allowing for modeling of OPPs, treat-
ment effects, treatment discontinuation, etc. that differ from the published 
model.
PRM52
ReConstRuCtion of inDiviDual Patient Data baseD on PublisheD 
kaPlan-MeieR CuRves: Case of RegoRafenib foR ColoReCtal CanCeR
Ali A.A., Adunlin G., Xiao H., Diaby V.
Florida A & M University, Tallahassee, FL, USA
Objectives: To conduct pharmacoeconomic analyses, both cost and effective-
ness data are required. Randomized controlled trials (RCTs) are often used as a 
source of efficacy data. As RCTs are often of short duration, efficacy data need to 
be extrapolated beyond the trial follow-up period to be fit for use in model-based 
pharmacoeconomic evaluations. However, RCTs usually report effectiveness data in 
terms of Kaplan-Meier (KM) estimates. As a result, researchers need to reconstruct 
individual patient data (IPD) from published KM curves of trials’ treatment arms 
to estimate their long-term effects. This study aims to reconstruct the survival 
benefits of regorafenib monotherapy for previously treated metastatic colorectal 
cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, 
phase 3 trial. MethOds: An algorithm developed by Guyot and colleagues was 
adopted to reconstruct IPD using R statistical package, based on the overall survival 
KM curves of the CORRECT trial. The reconstruction of IPD included the following 
steps: 1) extraction of coordinates from published KM curves, 2) data accuracy check, 
3) creation of a second dataset, and application of the algorithm. The results of the 
original trial were compared to the reconstructed data using graphical and quantita-
tive methods, for validation purposes. Results: Based on the IPD reconstruction, 
162 and 88 events occurred in the regorafenib and placebo groups respectively. The 
median overall survival time in the regorafenib arm was 6.5 months (95% CI 5.83, 
8.43) which is about the same as the original trial (6.4 months). In the placebo group, 
the median overall survival for the reconstruction data was 5.09 months (95% CI 
4.30, 6.81) compared to the trial median survival of 5.0 months. cOnclusiOns: 
The results of this study can be utilized to estimate transition probabilities for 
model-based pharmacoeconomic evaluations in the absence of individual patient 
data (IPD).
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lization and outcomes. Each factor was rated by three independent reviewers on a 
scale from 1 to 5, with 1 being limited use in economic modeling and 5 being highly 
useful for health economic modeling. Ratings were summed for each reviewer and 
averaged to produce a score out of 20 possible points. Results: Of the 14 real-world 
data sets assessed for utility in health economic modeling, claims data rated highest 
(15 out of 20) due to the availability of patient-level data from multiple sites of care, 
but lacked a link between utilization and patient outcomes. Despite the availability 
of patient outcomes associated with utilization with EMR data, the data set was rated 
the lowest (8 out of 20) due to its lack of nationally representative data and proprietary 
access. cOnclusiOns: Of the currently available real-world data sets, claims data 
was viewed as most useful for health economic models because they include patient-
level utilization data from multiple sites of care. Data mined from EMR represents 
a significant opportunity to link healthcare utilization with patient outcomes, but 
currently available EMR data lacks national representation and is expensive to obtain.
PRM60
a neW Cost-effeCtiveness fRaMeWoRk foR MoDeling PsoRiasis 
tReatMents
Graham C.1, Mollon P.2, Miles L.1, McBride D.1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland
Objectives: As more psoriasis treatments come to market in both new and exist-
ing drug classes, health care payers will need assistance in determining the most 
cost-effective regimen or sequence of regimens to control budgets. We sought to 
devise a cost-effectiveness modeling structure that will aid in decision making by 
highlighting differentiating factors between drugs and meet the changing needs of 
payers. MethOds: A systematic literature review was conducted to identify previ-
ously published cost-effectiveness models in moderate to severe psoriasis. As part of 
this review, we identified manufacturer submissions to health technology assessment 
(HTA) bodies and HTA responses/critiques of the submissions. The review showed that 
many previous models focused on one line of biologic therapy followed by standard of 
care. Additionally, Psoriasis Area Severity Index (PASI) response was limited in respect 
to both time periods considered and the categories of response modeled. Results: 
We developed a model structure that expanded the treatment/modeling paradigm by 
allowing a sequence of therapies (two lines of biologic therapies followed by standard 
of care). A short-term decision tree allows for a clinical determination of PASI response 
at 12 or 16 weeks post-initiation of therapy. Within the initial 12 or 16 week treatment 
period, we model the change in PASI levels over time to better reflect quality-of-life 
for patients on treatments with better speed of response. Following the decision tree, 
patients enter a semi-Markov (semi-Markov due to time dependent death probabili-
ties) to estimate long-term costs and outcomes. As new drugs allow some patients 
to achieve complete psoriasis clearance, we included a PASI 100 health state. Finally, 
we model disutilities related to severe adverse events to distinguish drugs with bet-
ter safety profiles. cOnclusiOns: This new framework will help decision makers 
by better differentiating psoriasis treatments and determining the optimum order 
of biologic therapies in the psoriasis treatment pathway.
PRM61
national buRDen of hosPitalizations foR neCRotizing enteRoColitis: 
Results fRoM the 2009 kiD’s inPatinet Database
Jiao X., Han X.
University of Southern California, Los Angeles, CA, USA
Objectives: To calculate national estimates of Necrotizing Enterocolitis (NEC)–
related hospitalization and associated use of health care resources to explore the 
effects of certain patient and hospital characteristics on use of hospital resources 
and length of stay in the United States. MethOds: Data from the 2009 Healthcare 
Cost and Utilization Project Kids’ Inpatient Database was used. Pediatric inpatient 
care in 4121 hospitals in 44 US states. Inpatient admissions with an International 
Classification of Diseases, Ninth Revision, Clinical Modification diagnosis of 
Necrotizing Enterocolitis. National estimates of NEC-associated hospitalizations 
were calculated. Potentially significant covariate associations were studied using 
hospital costs and Lengths of Stay as dependent variables. Predictors of high hos-
pitalization cost and prolonged length of stay were evaluated using multivariable 
logistic regression. Results: 2203 NEC-related hospitalizations occurred among 
infants in the United States in 2009, resulting in more than $213 Million in inpa-
tient hospitalization costs. Mean hospital costs and LOS were $110,951 and 51 days, 
respectively. Treatment type, died or not during hospitalization, comorbidities, 
complications, hospital type and hospital region, were significantly associated 
with higher total costs and longer length of stay. cOnclusiOns: For an infant 
disease with a rather low prevalence rate, the estimated annual inpatient pedi-
atric burden of NEC is a sizeable $213.3 million (2009 US$). As surgery treatment 
significantly influenced cost and length of hospitalization, there is an opportunity 
for reduction in inpatient burden if medications and outpatient treatments would 
improve for the treatment of NEC.
PRM62
ReDuCtion of influenza Disease Cost With suboPtiMal vaCCination
Bailey N., Wilson A., Li Y.
Anolinx, Murray, UT, USA
Objectives: The burden of disease due to seasonal influenza in the United States 
(US) remains high, despite vaccination efforts. In 2003 it was estimated that the 
direct medical costs averaged $10.4 billion, with a total economic burden estimated 
at $87.1 billion. Although the seasonal influenza vaccination is not always a con-
summate match, we suggest that the burden of disease is still greatly reduced 
even when vaccine match to circulating strain is suboptimal. This study aims to 
examine the decreased cost burden associated with the seasonal influenza vaccine, 
even in seasons of suboptimal match, by comparing historic published trends to 
large claims data. MethOds: Previously published data were compared to sea-
sonal influenza records, queried from a claims database containing over 55 million 
unique patients. Regression modeling was used to compare cost burden of persons 
and 0.0032 for obese men. Using overweight men as an example, the risk of death in 
this group was higher for diabetics than non-diabetics and increased with age and 
BMI. cOnclusiOns: Our results showed that women had a higher risk of diabetes 
but a lower risk of death for both diabetics and non-diabetics than men. Moreover, 
both risks increased with BMI and age. This joint estimation of the transition prob-
abilities in the Markov model overcomes the problem of negative probabilities 
resulting from separate estimations.
PRM56
tRee-baseD ClaiMs algoRithM foR MeasuRing PRe-tReatMent Quality 
of CaRe in MeDiCaRe DisableD hePatitis C Patients
Chirikov V.V.1, Shaya F.T.1, Onukwugha E.1, Mullins C.D.1, dosReis S.1, Howell C.D.2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Howard University College of 
Medicine, Washington, MD, USA
Objectives: To develop quality of care (QC) metrics using claims data in hepatitis 
C (HCV) Medicare patients with disability, a vulnerable population facing increased 
access barriers and representing the majority of HCV patients in Medicare, and 
quantify metrics’ correlation with treatment receipt. MethOds: We adapted 14 
Veterans Affairs-developed quality metrics (QM) for measurement in a cohort 
of 1,936 disabled HCV patients (2006-2009) with 6 months continuous Medicare 
parts A, B, D enrollment before diagnosis and no previous treatment. Based on 
the machine-learning principle of recursive partitioning, the proposed algorithm 
implements a random forest model of conditional inference trees, identifies the for-
est’s representative tree, and aggregates its terminal nodes into QC patient groups. 
Using linked county-level data from the Area Health Resource Files, we compared 
contextual characteristics across QC groups. Results: On average, 10.4% received 
peg-interferon. The five strongest predictors of treatment included “having received 
liver biopsy”, “HCV genotype testing”, “visit to specialist”, “confirmation of HCV 
viremia”, and “iron overload testing”. High QC (n= 360; treated= 33.3%) was defined 
for patients who had at least 2 from the abovementioned metrics. Good QC patients 
(n= 302; treated= 12.3%) had either “HCV genotype testing” or “visit to specialist”, 
while fair QC patients (n= 282; treated= 7.1%) only had “confirmation of viremia”. 
Patients with low QC (n= 992; treated= 2.5%) had none of the selected QMs. The 
algorithm accuracy of predicting treatment was 70% sensitivity and 78% specificity. 
Compared to those with fair or low QC, more high and good QC patients lived in rural 
or small town areas with lower access to specialized hospital and physician services 
and lower rates of insurance and education. cOnclusiOns: Higher quality of care 
correlated with higher treatment rates. Limited healthcare access among Medicare 
disabled patients with HCV was not associated with lower quality. Future research 
is needed to assess pre-treatment QM with newer HCV therapies.
PRM57
Cost-effeCtiveness evaluation of genotyPe-guiDeD antiPlatelet 
theRaPy veRsus univeRsal neW antiPlatelet theRaPy in Patients 
With aCute CoRonaRy synDRoMe
Jiang M., You J.
The Chinese University of Hong Kong, Shatin, Hong Kong
Objectives: Polymorphism of CYP2C19 affects metabolism and drug response of 
clopidogrel. New antiplatelet drugs such as prasugrel and ticagrelor are not affected 
by CYP2C19 polymorphism. CYP2C19 genetic testing could guide the selection of 
clopidogrel versus new antiplatelet agent (genotype-guided therapy). Published 
cost-effectiveness analyses of universal prasugrel or ticagrelor treatment versus 
genotype-guided therapy for patients with acute coronary syndrome (ACS) and 
planned percutaneous coronary intervention (PCI) yet showed conflicting results. 
We aimed to evaluate the cost-effectiveness of the new class of antiplatelet drugs 
versus genotype-guided therapy. MethOds: A lifelong Markov model was devel-
oped to compare universal new antiplatelet drugs treatment and genotype-guided 
therapy from the perspective of healthcare provider. In genotype-guided therapy 
arm, patients without CYP2C19 loss-of-function (LOF) allele would receive generic 
clopidogrel, while patients with at least one LOF allele would receive a new anti-
platelet agent. All clinical inputs were derived from published meta-analysis and 
clinical trials. Direct medical costs and quality-adjusted life-year (QALY) gained were 
the primary model outcomes. Results: Base-case results showed that genotype-
guided therapy cost $73,131 with 8.068 QALYs, while universal new antiplatelet 
therapy cost $79,179 with 7.946 QALYs. With a threshold of willingness-to-pay of 
$50,000 per QALY, no threshold values were identified in one-way sensitivity analy-
sis. The most influential factor was the probability of ischemic heart disease (IHD) 
state turned to death, followed by the possibility of post myocardial infarction state 
turned to death, cost of PCI and utility of IHD. In probabilistic sensitivity analysis, 
genotype-guided therapy was dominant with $6192 (95% CI 6170-6214) less costly 
and a gain of 0.2235 QALY (95% CI 0.2234-0.2236) compared with universal new anti-
platelet therapy. cOnclusiOns: Compared with universal use of new antiplatelet 
drugs, genotype-guided therapy seems to be a less costly and more effective clinical 
strategy for patients with ACS undergoing PCI.
PRM59
Real-WoRlD Data utility foR health eConoMiC MoDeling: an 
assessMent of CuRRent Data souRCes
Gavaghan M.1, Armstrong S.2, Taggart C.2, Garfield S.2
1GfK, Wayland, MA, USA, 2GfK Custom Research, Wayland, MA, USA
Objectives: Effective and robust health economic models are built on a foundation 
of reliable, accurate data sets. With the availability of various real-world data sets, 
the objective of this study was to examine several real-world data sets and rate their 
overall utility for use in health economic models in the United States. MethOds: 
Real-world data sets included in the assessment were one claims dataset, one elec-
tronic medical record (EMR) dataset, 11 state-level all payer claims databases (APCDs) 
and data from the Healthcare Cost and Utilization Project (HCUP). Factors assessed 
included: coverage of national versus regional population, inclusion of various sites 
of care, free/public access, and availability of longitudinal patient-level data on uti-
